{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:33:23Z","timestamp":1771670003470,"version":"3.50.1"},"reference-count":39,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1507\/endocrj.ej15-0448","type":"journal-article","created":{"date-parts":[[2015,9,19]],"date-time":"2015-09-19T18:00:58Z","timestamp":1442685658000},"page":"1059-1066","source":"Crossref","is-referenced-by-count":17,"title":["Simultaneous measurement of serum chemokines in autoimmune thyroid diseases: possible role of IP-10 in the inflammatory response"],"prefix":"10.1507","volume":"62","author":[{"given":"Izumi","family":"Hiratsuka","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyasu","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Tomatsu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Makino","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Caturegli P, Kimura H, Rocchi R, Rose NR (2007) Autoimmune thyroid diseases. <i>Curr Opin Rheumatol<\/i> 19: 44-48.","DOI":"10.1097\/BOR.0b013e3280113d1a"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Weetman AP (2004) Cellular immune responses in autoimmune thyroid disease. <i>Clin Endocrinol <\/i>(Oxf) 61: 405-413.","DOI":"10.1111\/j.1365-2265.2004.02085.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS (2011) Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. <i>J Interferon Cytokine Res<\/i> 31: 721-731.","DOI":"10.1089\/jir.2011.0049"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, et al. (2004) Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto&rsquo;s thyroiditis (Th1) and Graves&rsquo; disease (Th2). <i>Neuroimmunomodulation<\/i> 11: 209-213.","DOI":"10.1159\/000078438"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wakelkamp IMMJ, Gerding MN, van Der Meer JWC, Prummel MF, Wiersinga WM (2000) Both Th1- and Th2-derived cytokines in serum are elevated in Graves&rsquo; ophthalmopathy. <i>Clin Exp Immunol<\/i> 121: 453-457.","DOI":"10.1046\/j.1365-2249.2000.01335.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, et al. (2000) Serum concentrations of proinflammatory cytokines in Graves&rsquo; disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. <i>Eur J Endocrinol<\/i> 143: 197-202.","DOI":"10.1530\/eje.0.1430197"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tamaru M, Matsuura B, Onji M (1999) Increased levels of serum interleukin-12 in Graves&rsquo; disease. <i>Eur J Endocrinol<\/i> 141: 111-116.","DOI":"10.1530\/eje.0.1410111"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Miyauchi S, Matsuura B, Onji M (2000) Increased levels of serum interleukin-18 in Graves&rsquo; disease. <i>Thyroid<\/i> 10: 815-819.","DOI":"10.1089\/thy.2000.10.815"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Mysliwiec J, Kretowski A, Stepien A, Mironczuk K, Kinalska I (2003) Interleukin 18 and transforming growth factor beta1 in the serum of patients with Graves&rsquo; ophthalmopathy treated with corticosteroids. <i>Int Immunopharmacol<\/i> 3: 549-552.","DOI":"10.1016\/S1567-5769(03)00045-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. De Ciuceis C, Pilu A, Cappeli C, Porteri E, Zani F, et al. (2011) Decreased number of circulating endothelial progenitor cells in patients with Graves&rsquo; hyperthyroidism. <i>J Endocrinol Invest<\/i> 34: 335-339.","DOI":"10.1007\/BF03347455"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yamamoto K, Itoh M, Okamura T, Kimura M, Yokoyama A, et al. (2012) Relative levels of the inflammatory cytokine TNF&alpha; and the soluble CD40 ligand profile in serum correlate with the thyrotoxic activity of Graves&rsquo; diseases. <i>Thyroid<\/i> 22: 516-521.","DOI":"10.1089\/thy.2011.0222"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Kemp HE, Ajjan RA, Metcalfe RA, Watson PF, Weetman AP (2015) IL-14 and IL-16 are expressed in the thyroid of patients with either Graves&rsquo; disease or Hashimoto&rsquo;s thyroiditis. <i>Clin Endocrinol<\/i> (Oxf) doi:&nbsp;10.1111\/cen.12810","DOI":"10.1111\/cen.12810"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kimura H, Caturegli P (2007) Chemokine orchestration of autoimmune thyroiditis. <i>Thyroid<\/i> 17: 1005-1011.","DOI":"10.1089\/thy.2007.0267"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P (2007) Role of chemokines in endocrine autoimmune diseases. <i>Endocr Rev<\/i> 28: 492-520.","DOI":"10.1210\/er.2006-0044"},{"key":"15","unstructured":"15. Ashhab Y, Dominguez O, Sospedra M, Roura-Mir C, Lucas-Martin A, et al. (1999) A one-tube polymerase chain reaction protocol demonstrates CC chemokine overexpression in Graves&rsquo; disease glands. <i>J Clin Endocrinol Metab<\/i> 84: 2873-2882."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Simchen C, Lehmann I, Sittig D, Steinert M, Aust G (2000) Expression and regulation of regulated on activation, normal T cells expressed and secreted in thyroid tissue of patients with Graves&rsquo; disease and thyroid autonomy and in thyroid-derived cell populations. <i>J Clin Endocrinol Metab <\/i>85: 4758-4764.","DOI":"10.1210\/jc.85.12.4758"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, et al. (2003) Detection and localization of chemokine gene expression in autoimmune thyroid disease. <i>Clin Endocrinol<\/i> (Oxf) 59: 207-213.","DOI":"10.1046\/j.1365-2265.2003.01824.x"},{"key":"18","unstructured":"18. Weetman AP, Bennett GL, Wong WL (1992) Thyroid follicular cells produce interleukin-8. <i>J Clin Endocrinol Metab<\/i> 75: 328-330."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ruffilli I, Ferrari SM, Colaci M, Ferri C, Fallahi P, et al. (2014) IP-10 in autoimmune thyroiditis. <i>Horm Metab Res<\/i> 46: 597-602.","DOI":"10.1055\/s-0034-1382053"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fellahi P (2015) Autoimmune thyroid disorders. <i>Autoimmun Rev<\/i> 14: 174-180.","DOI":"10.1016\/j.autrev.2014.10.016"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Antonelli A, Ferrari SM, Gluggioli D, Ferrannini E, Ferri C, et al. (2014) Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. <i>Autoimmun Rev<\/i> 13: 272-280.","DOI":"10.1016\/j.autrev.2013.10.010"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Danilovic DL, Mendes-Correa MC, Chammas MC, Zambrini H, Barros RK, et al. (2013) Thyroid disturbance related to chronic hepatitis C infection: role of CXCL10. <i>Endocr J<\/i> 60: 583-590.","DOI":"10.1507\/endocrj.EJ12-0321"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. <i>N Engl J Med<\/i> 354: 610-621.","DOI":"10.1056\/NEJMra052723"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Zlotink A, Yoshie O, Nomiyama H (2006) The chemokine and chemokine receptors superfamilies and their molecular evolution. <i>Genome Biol<\/i> 7:243","DOI":"10.1186\/gb-2006-7-12-243"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Antonelli A, Rotondi M, Fallahi P, Ferrari SM, Paolicchi A, et al. (2006) Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. <i>Cytokine<\/i> 34: 32-38.","DOI":"10.1016\/j.cyto.2006.03.012"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, et al. (2006) Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves&rsquo; opthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. <i>J Clin Endocrinol Metab<\/i> 91: 614-620.","DOI":"10.1210\/jc.2005-1689"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Romagnani P, Rotondi M, Lazzeri E, Lasaqni L, Francalanci M, et al. (2002) Expression of IP-10\/CXCL10 and MIG\/CXCL9 in the thyroid and increased levels of IP-10\/CXCL10 in the serum of patients with recent-onset Graves&rsquo; disease. <i>Am J Pathol <\/i>161: 195-206.","DOI":"10.1016\/S0002-9440(10)64171-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, et al. (2006) Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves&rsquo; disease, and modulation by methimazole therapy. <i>Clin Endocrinol<\/i> (Oxf) 64: 189-195.","DOI":"10.1111\/j.1365-2265.2006.02447.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, et al. (2004) High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. <i>J Clin Endocrinol Metab<\/i> 89: 5496-5499.","DOI":"10.1210\/jc.2004-0977"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kokkotou E, Marafelia P, Mantzos EI, Tritos NA (2002) Serum monocyte chemoattractant protein-1 is increased in chronic autoimmune thyroiditis. <i>Metabolism <\/i>51: 1489-1493.","DOI":"10.1053\/meta.2002.34717"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Antonelli A, Rotondi M, Fallahi P, Romangnani P, Ferrari SM, et al. (2005) Increase of interferon-&gamma; inducible &alpha; chemokine CXCL10 but not &beta; chemokine CCL2 serum levels in chronic autoimmune thyroiditis. <i>Eur J Endocrinol<\/i> 152: 171-177.","DOI":"10.1530\/eje.1.01847"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, et al. (2006) Increased serum CXCL10 in Graves&rsquo; disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. <i>Eur J Endocrinol<\/i> 154: 651-658.","DOI":"10.1530\/eje.1.02137"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, et al. (2006) Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients active Graves&rsquo; disease, and modulation by methimazole therapy and thyroidectomy. <i>Br J Surg<\/i> 93: 1226-1231.","DOI":"10.1002\/bjs.5401"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, et al. (2007) Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves&rsquo; disease or toxic nodular goiter. <i>J Clin Endocrinol Metab<\/i> 92: 1485-1490.","DOI":"10.1210\/jc.2006-1571"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Domberg J, Chao L, Papewalis C, Pfleger C, Xu K, et al. (2008) Circulating chemokines in patients with autoimmune thyroid diseases. <i>Horm Metab Res<\/i> 40: 416-421.","DOI":"10.1055\/s-2008-1073151"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kasai K, Banba N, Motohashi S, Hattori Y, Manaka K, et al. (1996) Expression of monocyte chemoattractant protein-1 mRNA and protein in cultured human thyrocytes. <i>FEBS Lett<\/i> 394: 137-140.","DOI":"10.1016\/0014-5793(96)00935-0"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Gu X, Zheng L, Chen X, Ruan L, Zhang H, et al. (2012) Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy. <i>Horm Metab Res<\/i> 44: 482-487.","DOI":"10.1055\/s-0032-1308973"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Khan SS, Smith MS, Reda D, Suffredini AF, MacCoy JP (2004) Multiplex bead array assays for detection of soluble cytokines: comparisons sensitivity and quantitative values among kits from multiple manufacturers. <i>Cytometry<\/i> <i>B<\/i> <i>Clin Cytom<\/i> 61: 35-39.","DOI":"10.1002\/cyto.b.20021"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Liu MY, Xydakis AM, Hoogeveen RC, Jones PH, Smith EO, et al. (2005) Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 System. <i>Clin Chem<\/i> 51: 1102-1109.","DOI":"10.1373\/clinchem.2004.047084"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/62\/12\/62_EJ15-0448\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T15:51:14Z","timestamp":1498233074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/62\/12\/62_EJ15-0448\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej15-0448","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}